Acumen Pharmaceuticals Inc
(NAS:ABOS)
$
2.91
0.1 (3.56%)
Market Cap: 174.83 Mil
Enterprise Value: -57.43 Mil
PE Ratio: 0
PB Ratio: 0.72
GF Score: 30/100 - Q2 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 13, 2024$2.77 (+8.20%)Earnings
- Q1 2024 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2024$3.69 (+9.82%)Earnings
- Q4 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 26, 2024$3.75 (-11.76%)Earnings
- Acumen Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptNov 13, 2023$2.03 (+6.84%)Earnings
- Acumen Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 09, 2023
- Q2 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2023$7Earnings
- Acumen Pharmaceuticals, Inc. - Special Call TranscriptJul 17, 2023
- Acumen Pharmaceuticals Inc at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Q1 2023 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2023$5.73 (+18.14%)Earnings
- Q4 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMar 27, 2023$4.21 (+7.40%)Earnings
- Q2 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptAug 15, 2022$5.41 (+0.19%)Earnings
- Q1 2022 Acumen Pharmaceuticals Inc Earnings Call TranscriptMay 16, 2022Earnings
Acumen Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023 / 03:00PM GMT
Release Date Price:
$5.73
(-13.05%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
All right. Good morning. Welcome to the last day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here, and Charlie from my team is on stage with me. So we're thrilled today to do a quick fireside with Acumen Pharma. And speaking on behalf of Acumen, we have CEO, Dan O'Connell. Good to see you.
Daniel J. O;Connell
Acumen Pharmaceuticals, Inc. - CEO, President & Director
' -
Thanks, Geoff. Good to see you. Thanks for having us.
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Yes, of course.
Daniel J. O;Connell
Acumen Pharmaceuticals, Inc. - CEO, President & Director
' -
Good morning, Charlie.
Chen Yuan Yang
BofA Securities, Research Division - Research Analyst
Good morning.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)